Hypothesis: There is a marked variation in the outcome of patients with hepatocellular carcinoma with respect to race and ethnicity. Rates among African American and Hispanic individuals are elevated as compared with those among white individuals.
Design: Retrospective review of a prospective database. Demographic information, clinical staging, and other defining factors, including the absence or presence of hepatitis, cirrhosis, and alcohol abuse, were analyzed by patient interviews and review of the medical record.
Setting: Urban tertiary referral teaching hospital.
Patients: Patients diagnosed as having hepatocellular carcinoma between July 1997 and June 2003 (N = 264). Main Outcome Measure Overall survival rates.
Results: Based on multivariate analysis, race was identified as an independent predictor of survival. While there was no difference in the distribution of patient or tumor characteristics between the 2 groups, African American/Hispanic patients had a 5-year survival rate of 12%, which was significantly lower than that of white patients (50%; P = .001).
Conclusions: This study demonstrates a significant discrepancy in overall survival of African American/Hispanic patients as compared with that of white patients. The reason for this difference cannot be explained by patient or tumor characteristics or completely by treatment allocation. These data suggest that there may be socioeconomic, biological, and/or cultural determinants contributing to this observed difference in outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archsurg.139.9.992 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
c-FLIP/Ku70 complex; A potential molecular target for apoptosis induction in hepatocellular carcinoma.
Arch Biochem Biophys
January 2025
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address:
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide and the most common form of liver cancer. Despite global efforts toward early diagnosis and effective treatments, HCC is often diagnosed at advanced stages, where conventional therapies frequently lead to resistance and/or high recurrence rates. Therefore, novel biomarkers and promising medications are urgently required.
View Article and Find Full Text PDFSTAT3 Orchestrates Immune Dynamics in Hepatocellular Carcinoma: A Pivotal Nexus in Tumor Progression.
Crit Rev Oncol Hematol
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Precision Radiation Oncology, Hubei, China.
Hepatocellular carcinoma (HCC) presents a formidable challenge in oncology, attributed to its association with chronic liver diseases and global prevalence. The immune microenvironment profoundly influences HCC progression, balancing immune suppression and antitumor responses. The Signal Transducer and Activator of Transcription 3 (STAT3) is central to this equilibrium, orchestrating immune dynamics and intertwining tumor progression with immune evasion mechanisms.
View Article and Find Full Text PDFAutomated ultrasonography of hepatocellular carcinoma using discrete wavelet transform based deep-learning neural network.
Med Image Anal
January 2025
Department of Electrical and Computer Engineering, College of Information and Communication Engineering, Sungkyunkwan University, Suwon, 440-746, South Korea. Electronic address:
This study introduces HCC-Net, a novel wavelet-based approach for the accurate diagnosis of hepatocellular carcinoma (HCC) from abdominal ultrasound (US) images using artificial neural networks. The HCC-Net integrates the discrete wavelet transform (DWT) to decompose US images into four sub-band images, a lesion detector for hierarchical lesion localization, and a pattern-augmented classifier for generating pattern-enhanced lesion images and subsequent classification. The lesion detection uses a hierarchical coarse-to-fine approach to minimize missed lesions.
View Article and Find Full Text PDFLong-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
Hepatology
February 2025
Department of Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Background And Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and de novo HCC. Algorithms have been developed to stratify risk early after cure; however, data on long-term outcomes and the prognostic utility of these risk stratification algorithms at later time points are lacking.
View Article and Find Full Text PDFThe impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response.
Hepatology
January 2025
State Key Laboratory of Liver Research, Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!